Salivary gland cancers (SGCs) are rare malignancies that can arise from major (parotid, submandibular, sublingual) or minor glands present throughout the upper aerodigestive tract. These tumors encompass a diverse set of diseases representing more than 20 different histologic subtypes with distinct clinical behaviors, genomic/molecular profiles, and responsiveness to drug therapy [1–3]. Similar to other rare diseases, the lack of prospective drug trials focused on singular SGC tumor types makes evidence-based management a challenge.
https://ift.tt/2ka6OeN
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου